Read More

Why Is Dutch Pharma Argenx Trading Lower Today?

Tuesday, Argenx SE (NASDAQ: ARGX) released topline results from the ADVANCE-SC study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with primary immune thrombocytopenia (ITP), an autoimmune disorder defined by a significantly reduced number 

ARGX

Read More

Coherus And Junshi Biosciences Announce Publication Of Final Overall Survival Results Of JUPITER-02, A Phase 3 Trial Evaluating LOQTORZI As Treatment For Nasopharyngeal Carcinoma, In The Journal Of The American Medical Association

– Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with LOQTORZI plus chemotherapy significantly prolongs survival in patients with recurrent or metastatic NPC irrespective of PDL-1

CHRS

Read More

Novartis Outlines Pure-Play Strategy Progress After Generics Business Spin-Off

Novartis AG (NYSE: NVS) has outlined the progress made in delivering its pure-play strategy, focused on four core therapeutic areas (Cardiovascular-Renal-Metabolic, Immunology, Neuroscience, Oncology), two plus three technology platforms (Chemistry, Biotherapeutics, xRNA, Radioligand, Gene & Cell Therapy) in four priority geographies (US, China, Germany, Japan).

NVS